Summer Research Series

Our team attended four conventions in less than two months, in which we gave three talks and presented two research posters. The response to our research was fantastic, so we decided it would be fun to do a summer research series to share with everyone else. Enjoy and if you would like to know more about our analyses and data platform, email us directly to start a conversation.

---------------------------------------------------------

How Important is a CADTH Recommendation for Reimbursement in Canada?

The Canadian Agency for Drugs and Technologies in Health (CADTH) conducts health technology assessments, and provides recommendations for drug listings and reimbursements. When trying to make a drug available in Canada, how important is a positive recommendation? The results may surprise you!

Click here to read the full blog post.

Chart
Chart

---------------------------------------------------------

Diabetes Drug Approvals: Who’s Faster?

For Type-2 diabetes drugs, see the speed of FDA and EMA approvals through a different lens, and the importance of using the correct endpoint in measuring approval times. We performed an analysis comparing the relative speed of regulatory approvals by the FDA and the EMA (European Medicines Agency) for non-insulin­–dependent Type 2 diabetes drugs.

Click here to read the full blog post.

Chart
Chart

---------------------------------------------------------

Which Outcomes Matter in Solid-state Oncology?

Do HTA agencies value surrogate outcomes and if so, which ones are the most important in getting a positive recommendation? To have a better understanding, we analyzed 245 reviews for six solid-state oncology conditions that were published between 2005 and 2013 by 10 different Health Technology Assessments (HTA) agencies to determine if using PFS or DFS decreased their likelihood of a positive recommendation.

Click here to read the full blog post.

Chart
Chart

---------------------------------------------------------

Do Risk Management Schemes Influence HTAs?

Both the FDA and European Medicines Agency (EMA) have in place risk management processes to ensure that the benefits of a drug outweigh its risks. But are these REMS and RMP designations a red flag for reimbursement?

Click here to read the full blog post.

Chart
Chart

---------------------------------------------------------

Can “Valid Evidence” be Subjective among HTAs?

Our analysis breaks down the categories of disagreements among Health Technology Assessment (HTA) agencies and the implications.

Click here to read the full blog post.

Chart
Chart